Ascend supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.
Venatorx Pharmaceuticals, Inc. is a pharmaceutical company based in Malvern, Pennsylvania, established in 2010. The company specializes in the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections, including challenging conditions caused by pathogens such as MRSA, Pseudomonas, and Salmonella. Venatorx has developed a robust in-house research and development organization that has filed over 100 patents across various research initiatives. The company has received substantial funding from notable organizations, including the National Institute of Allergy and Infectious Diseases, Wellcome Trust, and the Biomedical Advanced Research and Development Authority, as well as private equity investments from firms like Versant Ventures and Abingworth. This support highlights Venatorx's commitment to addressing critical public health challenges related to resistant infections.
Anjarium Biosciences is a biotechnology company focused on engineering extracellular vesicles, particularly exosomes, to serve as advanced drug delivery systems for serious health conditions. By leveraging the natural communication network of the body, Anjarium transforms exosomes into effective therapeutic vehicles aimed at treating cancer and rare genetic diseases. Their proprietary Hybridosome® platform offers significant advantages in the design and application of these engineered exosomes, positioning the company at the forefront of developing targeted nanomedicines that could potentially improve patient outcomes in challenging therapeutic areas.
Effector Therapeutics is a biotechnology company based in San Diego, California, that specializes in the development of small molecule drugs aimed at treating cancer and other serious diseases. Founded in 2012, the company focuses on creating selective translation regulators that target the regulation of protein synthesis, a critical process in tumor growth and survival. By selectively blocking dysregulated translation, Effector Therapeutics aims to inhibit cancer cell proliferation while providing a potent and targeted therapeutic approach. This innovative strategy positions the company to potentially deliver new and effective treatments to patients facing challenging health conditions.
CymaBay Therapeutics is a clinical-stage biopharmaceutical company based in Newark, California, dedicated to developing therapies for liver and other chronic diseases with significant unmet medical needs. The company's lead product candidate, seladelpar, is a selective agonist of the peroxisome proliferator-activated receptor delta, which has completed Phase II clinical studies targeting conditions such as primary biliary cholangitis and sclerosing cholangitis, as well as nonalcoholic steatohepatitis. Additionally, CymaBay is developing MBX-2982, a selective oral G protein-coupled receptor agonist aimed at treating gut and liver diseases. The company also has a preclinical candidate, CB-001, which targets omega-3 fatty acid receptors. CymaBay has entered into development and licensing agreements with other pharmaceutical firms to explore treatments for metabolic diseases, including type 2 diabetes and gout. The company's commitment to advancing its pipeline reflects its focus on creating innovative medicines that can improve patient outcomes.
Glycomine, Inc. is a biotechnology company based in San Carlos, California, focused on developing nanomedicines for rare genetic disorders, particularly those related to protein and lipid glycosylation. Founded in 2014, Glycomine aims to address the significant unmet medical needs of patients suffering from approximately 7,000 rare disorders, many of which currently lack FDA-approved treatments. The company specializes in creating orphan drugs that combine replacement therapies—such as substrates, enzymes, and proteins—with innovative intracellular delivery systems. These bio-nano materials and ligands are designed to effectively target and deliver therapeutic molecules to the relevant cells in clinically significant organs, thereby enhancing treatment efficacy for patients with debilitating conditions caused by metabolic disorders and protein misfolding.
Adaptate is a biotherapeutics company that develops antibodies to modulate gamma delta T cells in situ. The company was founded in 2019 by Adrian Hayday and is headquartered in London.
X4 Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing novel therapeutics for primary immune deficiencies and cancer. Its lead drug candidate, mavorixafor, is an oral small molecule antagonist of the chemokine receptor CXCR4 and is currently undergoing various clinical trials, including a Phase III trial for patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, as well as trials for severe congenital neutropenia and clear cell renal cell carcinoma. The company is also advancing X4P-002, which targets glioblastoma multiforme, and X4P-003, aimed at treating primary immune deficiencies. Additionally, X4 Pharmaceuticals has a collaboration with Abbisko Therapeutics to explore mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in 2019.
Vera Therapeutics is engaged in the development of innovative gene editing solutions aimed at curing genetic diseases, particularly sickle cell disease and cystic fibrosis. The company utilizes a proprietary triplex gene editing platform to create a pipeline of therapeutic products targeting high-penetrance disease genes. Founded in 2016 and based in South San Francisco, California, Vera Therapeutics is dedicated to alleviating and potentially curing genetic disorders in affected patients.
Nido Surgical, Inc. is a medical device company founded in 2014 and located in Needham, Massachusetts. The company focuses on developing innovative surgical instruments for heart surgery, specifically through its flagship product, SEPIA. This Epicardial Ablation Solution is designed to address cardiac arrhythmias and facilitates video-endoscopic trans-cardiac surgical repairs within the beating heart. By enabling access through small incisions in the chest and heart wall, Nido's technology allows physicians to perform minimally invasive procedures without the need for cardiopulmonary bypass, enhancing surgical efficiency and patient recovery.
Atsena Therapeutics is a clinical-stage gene therapy company dedicated to developing ocular gene therapies aimed at reversing or preventing blindness. The company focuses on treating prominent forms of Leber congenital amaurosis and Usher syndrome. Utilizing adeno-associated virus technology, Atsena's pipeline is designed to address the challenges associated with inherited retinal diseases, providing innovative solutions to restore vision and improve the quality of life for patients affected by these conditions.
Reneo Pharmaceuticals develops therapies for patients with rare genetic mitochondrial diseases, which impact cellular metabolism and energy production. Founded in 2014 and based in San Diego, California, the company is focused on creating treatments that enhance mitochondrial function, thereby improving muscle health and overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes essential for energy metabolism and the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. By addressing the underlying metabolic deficiencies in these patients, Reneo aims to prevent muscle injury, weakness, and wasting, ultimately enhancing daily functioning for those with these orphan diseases.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Scorpion Therapeutics, Inc. is a biotechnology company focused on developing next-generation precision oncology technologies aimed at improving cancer treatment. Founded in 2020 and based in Boston, Massachusetts, the company specializes in creating precision oncology drugs that target known oncogenes, address currently undruggable cancer targets, and explore new therapeutic targets. By integrating advanced technologies in target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics seeks to expand the reach of precision medicine to a broader patient population. The company's approach is designed to unlock novel small-molecule drugs that can overcome the limitations of existing therapies, thereby enhancing treatment options for cancer patients.
NuCana plc is a clinical-stage biopharmaceutical company based in Edinburgh, United Kingdom, specializing in the development of advanced treatments for cancer. Utilizing its proprietary ProTide technology, NuCana aims to enhance the efficacy and safety of existing chemotherapy agents. The company's lead product candidate, Acelarin, is currently undergoing multiple clinical trials, including Phase III trials for biliary tract and metastatic pancreatic cancers, as well as Phase II trials for platinum-resistant ovarian cancer. Additionally, NuCana is advancing NUC-3373 and NUC-7738, both of which are in Phase I clinical trials targeting advanced solid tumors and hematological malignancies. The company collaborates with Cardiff University and its affiliated consultants to further its research and development efforts. Established in 1997, NuCana has shifted its focus towards addressing significant unmet medical needs in oncology, supported by a management team with extensive experience in building successful biopharmaceutical ventures.
Nido Biosciences, Inc., founded in 2018 and based in Boston, Massachusetts, operates in the healthcare services sector. The company specializes in biotechnology and personal health, aiming to innovate within these fields. Currently in stealth mode, Nido Biosciences is focused on developing solutions that address unmet needs in healthcare and personal health management.
Q32 Bio is a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Q32 Bio consists of a team of scientists and industry veterans with strong expertise in immunology. The team has a strong track record of discovering and developing new and innovative therapies.
Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare endocrine disorders. Founded in 2014 and based in Daly City, California, the company is primarily focused on its lead candidate, tildacerfont, which is being evaluated in Phase II clinical trials for classic congenital adrenal hyperplasia (CAH) in both adults and children. Tildacerfont aims to be the first non-steroidal treatment that enhances disease control while minimizing the reliance on steroids for managing CAH. Additionally, Spruce Biosciences is exploring tildacerfont's potential applications in treating polycystic ovary syndrome in women. The company has also entered a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications. Through its efforts, Spruce Biosciences seeks to significantly improve the quality of life for patients with rare endocrine disorders who have historically been underserved by medical advancements.
Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.
Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.
Jasper Therapeutics, Inc. is a biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company is focused on creating safer and more effective conditioning agents to enhance the efficacy of stem cell transplants and gene therapies. Its lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by clearing hematopoietic stem cells from bone marrow. JSP191 targets the CD117 receptor, which is expressed on hematopoietic stem and progenitor cells, thereby facilitating safer transplant procedures and potentially broadening the application of curative therapies.
IFM Therapeutics specializes in developing small molecule medicines that target the innate immune system to address complex challenges in treating inflammatory and autoimmune disorders, as well as cancer. The company collaborates with academic partners to leverage expertise in innate immunity alongside experienced drug discovery professionals. Its subsidiary, IFM Due, focuses on discovering and developing antagonists of the cGAS/STING pathway, aiming to treat conditions such as inflammation, neuroinflammation, autoimmunity, and cancer. Additionally, IFM Discovery, a newly established incubator within the company, is engaged in advancing a portfolio of genetically validated targets for next-generation therapies addressing inflammation, neuroinflammation, autoimmunity, and fibrosis. Through these initiatives, IFM Therapeutics seeks to enhance immune response and improve the quality of life for patients facing serious health challenges.
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for rare diseases. The company’s primary focus is on Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet designed to treat Prader-Willi Syndrome (PWS). DCCR, which contains diazoxide choline, a choline salt of diazoxide, is currently undergoing evaluation in a Phase III clinical development program. Founded in 1999 and headquartered in Redwood City, California, Soleno Therapeutics was formerly known as Capnia, Inc. and underwent a name change in May 2017.
NIR is a biopharmaceutical company developing a suite of small-molecule antagonists targeting inappropriate inflammatory responses of the innate immune system via the NLRP3 pathway, which is believed to underlie a variety of serious diseases. The Company is developing chemically distinct systemic, gut-directed and CNS-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurodegenerative diseases. IFM Tre was founded in 2017 and headquartered in Boston, Massachusetts.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
Attenua, Inc. is a biotechnology company based in San Mateo, California, founded in 2015. The company focuses on developing non-narcotic medicines specifically aimed at treating chronic cough and other chronic respiratory disorders. Recognizing the unmet needs in therapeutic areas often overlooked by larger pharmaceutical companies, Attenua seeks to uncover small molecule drugs that could significantly benefit patients. The team comprises experienced scientists and former advisors from major pharmaceutical firms, bringing extensive expertise in drug development. By prioritizing the discovery of innovative therapies, Attenua aims to improve the quality of life for individuals suffering from debilitating chronic conditions.
Private Equity Round in 2018
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Nouscom is a biotechnology company focused on developing innovative immunotherapy solutions for cancer treatment. Headquartered in Basel, Switzerland, with operations in Rome, Italy, the company specializes in engineered viral vector vaccines. Their platform is designed to express long strings of tumor neoantigens, facilitating the induction of strong antitumor T-cell responses to enhance cancer-specific cellular immunity. The leadership team, including experienced entrepreneurs like Prof. Riccardo Cortese, brings a wealth of expertise from previous successful ventures in the field of oncolytic and genetic vaccines.
VirionHealth Limited is a biotechnology company based in Coventry, United Kingdom, founded in 2015. The company specializes in developing innovative therapeutics and biological treatments for respiratory viral infections, with a particular emphasis on influenza and respiratory syncytial viruses. VirionHealth is known for its pioneering DI platform technology, which aims to create a new class of biological antiviral agents effective against a variety of infectious diseases. Through its research and development efforts, VirionHealth seeks to advance the prevention and treatment of significant viral health threats.
Virion Biotherapeutics is a developer of biological antivirals aimed at improving therapeutics for respiratory viral infections. The company specifically focuses on the prevention and treatment of influenza and respiratory syncytial virus (RSV). By offering broad-spectrum therapies for these infections, Virion seeks to simplify and accelerate treatment processes for healthcare providers, eliminating the need for differential diagnosis. Through its innovative approach, Virion Biotherapeutics aims to enhance patient care in the realm of respiratory illnesses.
GTx, Inc. is a company of pioneering and driven individuals who are delivering better medicines with new science through established pathways.
Realm Therapeutics is a biopharmaceutical company based in Malvern, Pennsylvania, focused on leveraging proprietary technologies to enhance health outcomes for adults and children. Initially engaged in developing therapies for immune-mediated diseases, the company's drug development efforts are centered on creating small molecule therapies aimed at inflammatory diseases, with applications in dermatology and ophthalmology, as well as potential use in various other conditions. Founded in 2016 and previously known as PuriCore plc, Realm Therapeutics currently operates as a subsidiary of ESSA Pharma Inc. The company is exploring opportunities for investment, partnerships, or acquisitions to further its capabilities in the life sciences sector.
Venatorx Pharmaceuticals, Inc. is a pharmaceutical company based in Malvern, Pennsylvania, established in 2010. The company specializes in the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections, including challenging conditions caused by pathogens such as MRSA, Pseudomonas, and Salmonella. Venatorx has developed a robust in-house research and development organization that has filed over 100 patents across various research initiatives. The company has received substantial funding from notable organizations, including the National Institute of Allergy and Infectious Diseases, Wellcome Trust, and the Biomedical Advanced Research and Development Authority, as well as private equity investments from firms like Versant Ventures and Abingworth. This support highlights Venatorx's commitment to addressing critical public health challenges related to resistant infections.
GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
GammaDelta Therapeutics is developing the potential of gamma delta (γδ) cells to create improved immunotherapy of cancer and other serious diseases. The company plans to exploit unique properties of tissue resident γδ T cells for effective immunotherapy.
IFM Therapeutics specializes in developing small molecule medicines that target the innate immune system to address complex challenges in treating inflammatory and autoimmune disorders, as well as cancer. The company collaborates with academic partners to leverage expertise in innate immunity alongside experienced drug discovery professionals. Its subsidiary, IFM Due, focuses on discovering and developing antagonists of the cGAS/STING pathway, aiming to treat conditions such as inflammation, neuroinflammation, autoimmunity, and cancer. Additionally, IFM Discovery, a newly established incubator within the company, is engaged in advancing a portfolio of genetically validated targets for next-generation therapies addressing inflammation, neuroinflammation, autoimmunity, and fibrosis. Through these initiatives, IFM Therapeutics seeks to enhance immune response and improve the quality of life for patients facing serious health challenges.
Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.
Tizona Therapeutics, Inc. is an immunotherapy company focused on developing treatments for cancer and autoimmune diseases. Founded in 2014 and located in South San Francisco, California, the company is known for its innovative products, including an Anti-CCR4 antibody aimed at cancer treatment, as well as IL-35 antagonists and agonists that target immune response modulation. Tizona is actively collaborating with its scientific founders to enhance understanding of the role of regulatory T cells in tumor immunosuppression, which is crucial for developing effective therapies. By targeting specific cell types and biological mechanisms responsible for immune suppression in the tumor microenvironment, Tizona aims to provide patients with durable and complete remissions from their conditions.
Effector Therapeutics is a biotechnology company based in San Diego, California, that specializes in the development of small molecule drugs aimed at treating cancer and other serious diseases. Founded in 2012, the company focuses on creating selective translation regulators that target the regulation of protein synthesis, a critical process in tumor growth and survival. By selectively blocking dysregulated translation, Effector Therapeutics aims to inhibit cancer cell proliferation while providing a potent and targeted therapeutic approach. This innovative strategy positions the company to potentially deliver new and effective treatments to patients facing challenging health conditions.
Kesios Therapeutics Limited develops small molecule drugs for haematological malignancies, such as multiple myeloma The NF-κB Pathway and Novel Oncology Target (GADD45β/MKK7), Research and Development pipeline and related indications. The company was incorporated in 2012 and is based in Cambridge, United Kingdom.
Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains causing significant invasive pneumococcal disease and antibiotic resistance; VAX-A1, a conjugate vaccine candidate for protection against subtypes of Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was founded in 2013 and is headquartered in Foster City, California.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
Median Technologies is a company that develops and markets software products and platforms for medical image analysis, focusing on oncology clinical trials and cancer screening. Founded in 2002 and based in Valbonne, France, it offers solutions such as iBiopsy, an AI-powered platform that aids in biomarker identification and patient profiling through CT scan similarity searches, and iSee, which facilitates image analysis and management in clinical trials. The company aims to standardize and automate the interpretation of medical images to enhance the diagnosis of cancer and evaluate treatment responses. Median Technologies serves both drug development and patient care markets, partnering with contract research organizations and Canon to deliver integrated imaging services and innovate new imaging technologies.
CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.
CRISPR Therapeutics AG is a gene editing company dedicated to developing transformative gene-based medicines for serious human diseases using its proprietary CRISPR/Cas9 technology. This revolutionary platform allows for precise modifications to genomic DNA, enabling the company to target a variety of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The lead product candidate, CTX001, is an ex vivo CRISPR gene-edited therapy aimed at treating transfusion-dependent beta thalassemia and severe sickle cell disease by engineering patients' hematopoietic stem cells to produce elevated levels of fetal hemoglobin. Additionally, CRISPR Therapeutics is advancing other therapies, including CTX110, an allogeneic CAR-T therapy for certain malignancies, and additional programs targeting conditions such as multiple myeloma, solid tumors, diabetes, and various genetic disorders. The company collaborates with strategic partners such as Bayer Healthcare, Vertex Pharmaceuticals, and ViaCyte, and is headquartered in Zug, Switzerland.
Chiasma (Israel) Ltd. is a biopharmaceutical company specializing in the development of oral drugs utilizing its proprietary Transient Permeability Enhancer technology. Founded in 2001 and based in Ness Ziona, Israel, the company focuses on transforming injectable drugs into oral formulations, thereby enhancing their absorption and potentially enabling new therapeutic indications. Its primary product is oral octreotide acetate, designed for the treatment of acromegaly, a rare condition. Chiasma's pipeline includes novel drugs aimed at addressing unmet medical needs in well-defined markets, with a particular emphasis on orphan indications. The company operates as a subsidiary of Chiasma, Inc., and is dedicated to improving the treatment options for patients with rare and debilitating diseases.
Personalis combines expertise both in the technology of sequencing and in interpretation, with an extensive history of peer-reviewed publication and commercial success. Broad adoption of medical genome interpretation will require accuracy befitting regulatory approval, both invariant detection and interpretation.
The company was founded in 2011 and is based in Menlo Park, California.
Median Technologies is a company that develops and markets software products and platforms for medical image analysis, focusing on oncology clinical trials and cancer screening. Founded in 2002 and based in Valbonne, France, it offers solutions such as iBiopsy, an AI-powered platform that aids in biomarker identification and patient profiling through CT scan similarity searches, and iSee, which facilitates image analysis and management in clinical trials. The company aims to standardize and automate the interpretation of medical images to enhance the diagnosis of cancer and evaluate treatment responses. Median Technologies serves both drug development and patient care markets, partnering with contract research organizations and Canon to deliver integrated imaging services and innovate new imaging technologies.
Paratek Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapies for life-threatening infectious diseases and other serious health conditions. The company’s lead products include NUZYRA, an oral and intravenous broad-spectrum antibiotic effective against community-acquired bacterial pneumonia and acute bacterial skin infections, and SEYSARA, a tetracycline antibiotic for treating moderate to severe acne vulgaris. Paratek’s research is anchored in tetracycline chemistry and biology, and the company actively collaborates with partners such as Zai Lab and Allergan, as well as academic institutions like Tufts University. Additionally, Paratek engages in cooperative research with the U.S. Army Medical Research Institute of Infectious Diseases to explore treatment options against infectious agents. Founded in 1996, Paratek continues to expand its focus on addressing severe diseases, including research into multiple sclerosis and systemic inflammatory conditions.
On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Senseonics Holdings, Inc. is a medical technology company based in Germantown, Maryland, specializing in continuous glucose monitoring (CGM) systems for individuals with diabetes, primarily in Europe. Founded in 1996, the company develops advanced implantable CGM products, including Eversense and Eversense XL, which monitor glucose levels for up to 90 and 180 days, respectively. Using innovative fluorescence sensing technology, these systems are designed to provide high accuracy and stability throughout their extended sensor life. The company aims to empower people with diabetes to manage their condition more effectively and confidently through its CGM solutions, which also include a smart transmitter and a mobile app. A significant portion of Senseonics' revenue is generated from markets outside the United States.
Wilson Therapeutics is a biopharmaceutical company located in Stockholm, Sweden, focusing on the development of innovative therapies for rare diseases, particularly Wilson Disease. The company’s primary product, Decuprate®, is being investigated as a new treatment option for this condition and is currently undergoing evaluation in a Phase II clinical study involving patients with Wilson Disease. By targeting copper-mediated disorders, Wilson Therapeutics aims to address unmet medical needs in this specialized area of healthcare.
Pixium Vision SA is a Paris-based company focused on developing implantable medical devices to address blindness caused by the degeneration of retinal photoreceptor cells. The company is known for its bionic vision system, the PRIMA System, which aims to restore vision and enhance the quality of life for individuals suffering from vision loss. Additionally, Pixium Vision is advancing its retinal implant technologies through devices such as the IRIS1, currently in clinical trials, and the upcoming IRIS2, which promises improved visual acuity. The company is also working on the IRIS3 sub-retinal implant, leveraging cutting-edge advancements in neural processing and micro-electronics. Founded in 2011 as a spin-out from the Vision Institute and Université Pierre et Marie Curie, Pixium collaborates with leading institutions, including Stanford University and Moorfields Eye Hospital, to further its research and development efforts. The company is supported by prominent European venture capital firms.
Personalis combines expertise both in the technology of sequencing and in interpretation, with an extensive history of peer-reviewed publication and commercial success. Broad adoption of medical genome interpretation will require accuracy befitting regulatory approval, both invariant detection and interpretation.
The company was founded in 2011 and is based in Menlo Park, California.
Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.
Effector Therapeutics is a biotechnology company based in San Diego, California, that specializes in the development of small molecule drugs aimed at treating cancer and other serious diseases. Founded in 2012, the company focuses on creating selective translation regulators that target the regulation of protein synthesis, a critical process in tumor growth and survival. By selectively blocking dysregulated translation, Effector Therapeutics aims to inhibit cancer cell proliferation while providing a potent and targeted therapeutic approach. This innovative strategy positions the company to potentially deliver new and effective treatments to patients facing challenging health conditions.
GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in the discovery and development of gene therapy treatments for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. The company utilizes two primary technology platforms: mitochondrial targeting sequences and optogenetics, aiming to preserve or restore vision in patients affected by severe retinal diseases. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III clinical trials for treating Leber hereditary optic neuropathy associated with ND4 gene mutations, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. Additionally, GenSight is advancing various preclinical programs targeting both ophthalmic and neurodegenerative conditions, reflecting its commitment to innovative solutions for patients with significant vision impairment or blindness. GenSight Biologics was founded in 2012.
Avedro, Inc. is an ophthalmic pharmaceutical and medical device company that specializes in developing and commercializing products for treating corneal disorders, particularly those associated with corneal weakness. The company's primary offering is the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems, designed to deliver ultraviolet A (UVA) light alongside various single-use riboflavin drug formulations. This platform addresses corneal ectatic disorders and refractive conditions, with specific applications in treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also offers the Keraflex procedure, a non-invasive technique for corneal reshaping that preserves corneal integrity. The company's products are primarily marketed to ophthalmologists, hospitals, and ambulatory surgery centers both in the United States and internationally through a network of distributors. Avedro, which was incorporated in 2002 and is headquartered in Waltham, Massachusetts, operates as a subsidiary of Glaukos Corporation.
Gynesonics, Inc. is a healthcare company specializing in the development of minimally invasive solutions for symptomatic uterine fibroids in women. The company offers the Sonata System, which utilizes sonography-guided transcervical fibroid ablation to treat these conditions under intrauterine sonography guidance. Founded in 2005, Gynesonics is headquartered in Redwood City, California, with an additional location in Beuningen, the Netherlands. The company serves customers worldwide, focusing on providing advanced, incision-free treatment options for uterine conditions.
Avillion LLP, a drug development company, focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers opportunities to partner late phase therapeutic projects for approval, and to accelerate their availability to the market. The company also provides global clinical trial, global regulatory, and CRO management services. It serves pharmaceutical and biotechnology companies. The company was incorporated in 2012 and is based in London, United Kingdom.
Labcyte Inc. is a specialized laboratory instrumentation company based in San Jose, California, established in 2000. It focuses on acoustic droplet ejection (ADE) technology, which enables the precise dispensing of nanoliter-scale droplets for various life sciences applications, including drug discovery, genomics research, cancer research, and diagnostic testing. The company's flagship product, Echo, utilizes a focused beam of acoustic energy to transfer small volumes of liquids with high accuracy and minimal waste, thereby reducing consumable costs. Labcyte also offers a range of automation systems, laboratory workstations, and control software to enhance laboratory efficiency. As a subsidiary of Beckman Coulter, Inc., Labcyte has expanded its presence internationally, with offices in countries such as Canada, the United Kingdom, Australia, and several others across Asia. The company was previously known as Picoliter Inc. until it rebranded in 2003.
Chiasma (Israel) Ltd. is a biopharmaceutical company specializing in the development of oral drugs utilizing its proprietary Transient Permeability Enhancer technology. Founded in 2001 and based in Ness Ziona, Israel, the company focuses on transforming injectable drugs into oral formulations, thereby enhancing their absorption and potentially enabling new therapeutic indications. Its primary product is oral octreotide acetate, designed for the treatment of acromegaly, a rare condition. Chiasma's pipeline includes novel drugs aimed at addressing unmet medical needs in well-defined markets, with a particular emphasis on orphan indications. The company operates as a subsidiary of Chiasma, Inc., and is dedicated to improving the treatment options for patients with rare and debilitating diseases.
Sonitus Medical Inc., is a privately held medical device company committed to providing innovative and clinically effective hearing solutions that Otologists, ENTs, and Audiologists can use to help their patients rejoin the conversation of life. As an emerging leader in bone conduction hearing devices, Sonitus Medical currently markets the SoundBite Hearing System, the world's first non-invasive and removable hearing solution that imperceptibly transmits sound via teeth. Relying on the principle of bone conduction, this nearly invisible ITM (in-the-mouth) hearing system is a simple and non-surgical solution that is currently FDA cleared as a prosthetic device for the treatment of single sided deafness and conductive hearing loss. Intended future applications for this platform technology include indications for hearing disorders such as mixed hearing loss and tinnitus, as well as consumer and covert communications. Founded in June 2006, Sonitus Medical is headquartered in San Mateo, California.
Sientra, Inc. is a medical device company based in Santa Barbara, California, specializing in the plastic surgery and aesthetics market. The company develops and markets a range of products, including silicone gel breast implants, breast tissue expanders, and silicone scar treatment solutions, aimed at enhancing cosmetic and reconstructive surgery procedures. Sientra focuses on providing innovative and intuitive solutions for plastic surgeons, offering both round and shaped breast implant options to meet diverse patient needs. Through its commitment to quality and innovation, Sientra serves as a key player in the surgical aesthetics industry.
Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.
Prosensa is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. It is particularly focused on addressing genetic disorders, with a primary emphasis on neuromuscular conditions. The company recognizes significant market opportunities in the healthcare sector for innovative products targeting genetic disorders, anti-infectives, and oncology. To maximize commercial potential, Prosensa plans to leverage its strong intellectual property position while primarily outsourcing its operations to specialized organizations. Through this strategy, the company aims to develop novel therapeutics that can address unmet medical needs in various therapeutic areas.
On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.
Personalis combines expertise both in the technology of sequencing and in interpretation, with an extensive history of peer-reviewed publication and commercial success. Broad adoption of medical genome interpretation will require accuracy befitting regulatory approval, both invariant detection and interpretation.
The company was founded in 2011 and is based in Menlo Park, California.
MD On-Line Inc. is a prominent provider of electronic data interchange (EDI) solutions that streamline interactions between healthcare providers and payers in the United States. The company facilitates electronic data capture, claim submissions, and transactional data processing, enhancing the efficiency of the healthcare system. MD On-Line's services include real-time eligibility verification, referrals, claim status inquiries, and electronic remittance advice. Its offerings are co-branded and endorsed by over 30 major insurers, making a significant impact in healthcare practices of all sizes. With a network that encompasses more than 2,000 payer organizations and serves over 45,000 healthcare providers nationwide, MD On-Line is dedicated to improving the cost-effectiveness of healthcare by eliminating inefficiencies in transactions.
Lombard Medical develops, manufactures and markets an innovative range of minimally invasive abdominal aortic aneurysm endovascular repair products.
Syntaxin is a biopharmaceutical company that engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases. The biopharmaceutical company's proprietary technology platform enables the engineering of bacterial proteins by domain substitution, to produce novel cell-specific biotherapeutics that inhibit cell secretion. These products can have therapeutic effects in a wide range of indications.
IS Pharma plc, based in Chester, United Kingdom, specializes in the development, acquisition, and commercialization of pharmaceuticals and medical devices, primarily in the fields of critical care, oncology, and neurology. The company offers a range of commercial products, including Volplex, a sterile plasma substitute for intravenous use, and various topical analgesics such as Cryogesic and Dermogesic. Additionally, IS Pharma markets Mysoline for epilepsy treatment, Aloxi for nausea prevention, and Isoplex for fluid volume replacement. The company’s late-stage development pipeline includes Haemopressin for treating bleeding oesophageal varices, Acoranil for patients unable to take tablets, AquiHex to reduce hospital-acquired infections, and Gentispray for otitis externa. IS Pharma also collaborates on partnered products like OptiFlo and ContiSol catheter irrigation solutions, and is developing Micelle Nanotechnology for drug delivery in interstitial cystitis. The company was previously known as Maelor plc before rebranding in April 2008.
Pathwork Diagnostics, located in Redwood City, California, specializes in molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. The test leverages genomic information from a tumor to enhance diagnostic precision and can be applied to various specimen types, including frozen tissue and formalin-fixed, paraffin-embedded samples. Through its advanced diagnostic solutions, Pathwork Diagnostics aims to improve clinical outcomes in cancer care.
Avila Therapeutics, Inc. is a biotechnology company based in Waltham, Massachusetts, that specializes in the design and development of covalent drugs targeting viral infections, cancers, and autoimmune diseases. One of its key products is AVL-181, a small molecule designed to inhibit the protease of the hepatitis C virus. Founded in 2006, Avila Therapeutics has entered into a strategic alliance with Sanofi-Aventis and, as of 2012, operates as a subsidiary of Celgene Corporation. The company's innovative approach focuses on creating therapies that can provide significant benefits in the treatment of challenging medical conditions.
Oxagen Limited, a biopharmaceutical company, develops and commercializes anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhinoconjunctivitis. Its drug programs target the CRTH2 receptor that initiates and maintains allergic conditions. The company develops a pipeline of small molecule drugs. It serves customers in the United Kingdom, Russia, CIS countries, and internationally. Oxagen Limited was incorporated in 1996 and is based in London, United Kingdom.
PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.
Amarin Corporation plc is a pharmaceutical company dedicated to developing and commercializing therapeutics for cardiovascular diseases in the United States. Its primary product, Vascepa, is a prescription omega-3 fatty acid capsule designed to reduce triglyceride levels in adults with severe hypertriglyceridemia. The company is also conducting research on the REDUCE-IT study, which targets patients with high triglyceride levels who are undergoing statin therapy. Amarin markets its products primarily to wholesalers and specialty pharmacy providers, utilizing a direct sales force. The company has partnered with Mochida Pharmaceutical Co., Ltd. to further develop and commercialize products based on the active ingredient in Vascepa, eicosapentaenoic acid. Founded in 1989 and headquartered in Dublin, Ireland, Amarin has a research and development facility in Mystic, Connecticut, and focuses on lipid science to enhance cardiovascular disease management.
Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Headquartered in Emeryville, California, Zogenix is advancing several product candidates, including Fintepla, a low-dose fenfluramine currently undergoing Phase III clinical trials for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. The company is also investigating MT1621, a therapy for inherited mitochondrial DNA depletion disorder. Additionally, Zogenix has established a collaboration with Tevard Biosciences to explore gene therapies for Dravet syndrome and related genetic epilepsies. The company aims to address significant unmet medical needs in the pharmaceutical landscape, particularly for conditions affecting the central nervous system and chronic pain management. Founded in 2006, Zogenix was previously known as SJ2 Therapeutics, Inc. before rebranding in August 2006.
Intellikine works in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway. Intellikine is committed to building an exceptional team and a powerful discovery platform that rapidly generates small molecule kinase inhibitor drug candidates that will become the next generation of medical breakthroughs.
Chroma Therapeutics Ltd. is a biotechnology company based in Abingdon, United Kingdom, specializing in the discovery and development of novel small molecule drugs targeting cancer and inflammatory disorders. Founded in 2000, Chroma leverages chromatin biology and innovative cell accumulation techniques to create its product pipeline. Key products include Tosedostat, an oral aminopeptidase inhibitor; CHR-3996, an optimized histone deacetylase inhibitor designed for cancer treatment; and CHR-2845, focused on hematological malignancies. The company is recognized for its systematic assembly of intellectual property in chromatin biology and has established a strong network of academic collaborations to enhance its research and development efforts.
Clovis Oncology, Inc. is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of anti-cancer agents in the United States, Europe, and other international markets. The company is known for its product Rubraca (rucaparib), an oral small molecule inhibitor designed to treat recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. Additionally, Clovis is developing lucitanib, an oral inhibitor that targets various tyrosine kinase receptors associated with tumor growth. The company utilizes precision medicine and companion diagnostics to ensure that therapies are directed toward patients most likely to benefit from them. Clovis Oncology distributes its products primarily through specialty distributors and pharmacy providers. Founded in 2009 and headquartered in Boulder, Colorado, the company has established partnerships and licensing agreements with multiple pharmaceutical organizations, enhancing its ability to innovate within the oncology sector.
SFJ Pharmaceuticals, Inc. is a specialty pharmaceutical company based in Pleasanton, California, that focuses on the clinical development and registration of pharmaceutical products, particularly in Japan. Established in 2008, the company aims to facilitate the accelerated availability of innovative drugs by providing funding and strategic development expertise to pharmaceutical and biotech partners. SFJ Pharmaceuticals addresses challenges in drug development, such as budget cuts due to patent expirations and limited external funding for biotech firms. By assuming 100% of the clinical and regulatory risk, SFJ enables its partners to advance their critical drug candidates without adding financial strain. The company employs a pharmaceutical product registration platform that manages late-stage trial design, clinical execution, and regulatory processes, thereby aiding medical professionals in expediting the development of drug candidates across various therapeutic areas.
Algeta ASA is an oncology company based in Oslo, Norway, dedicated to developing targeted therapies for cancer patients using its innovative alpha-pharmaceutical platform. The company's lead product, radium-223 dichloride, has successfully completed Phase III clinical trials for treating castration-resistant prostate cancer with bone metastases. Additionally, Algeta is advancing the development of thorium-227 conjugates, which involve linking the alpha-emitter to tumor-targeting molecules, currently in the preclinical phase. Algeta has established a collaboration with Bayer Pharma AG for the global development and commercialization of radium-223. Founded in 1997, the company originally operated under the name Anticancer Therapeutic Inventions AS before rebranding as Algeta ASA in 2003.
Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.
Synosia Therapeutics develops and intends to commercialise products for unmet medical needs in psychiatry and neurology. The privately-owned company has in its pipeline six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications to extend their reach into neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.
Broncus Medical develops innovative diagnostic and therapeutic navigation technologies aimed at treating lung diseases. The company offers a range of products, including the Archimedes System, which features bronchoscopic trans-parenchymal needle access for virtual bronchoscopic planning and navigation, and the Lungpoint Virtual Bronchoscopic Navigation system that enables real-time navigation within the lungs for biopsy procedures. Additionally, Broncus is advancing its Exhale product line, which includes the Airway Bypass procedure, a minimally-invasive treatment for homogeneous emphysema, a prevalent form of the disease. The company is currently conducting the pivotal EASE Trial to evaluate this treatment. Founded in 1997 and originally named Broncus Technologies, the company is headquartered in San Jose, California, with additional operations in Shanghai, China, and Mountain View, California. Broncus Medical focuses on addressing the unmet medical needs in interventional pulmonology, improving the diagnosis and treatment of lung cancer and chronic obstructive pulmonary disease (COPD).
Micromet is a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment and control of cancer. Their lead product candidate, Canvaxin, is one of a new class of products being developed in the area of specific active immunotherapy, also known as therapeutic cancer vaccines.
On June 30, 2020, Valeritas Holdings, Inc. went out of business as per its Chapter 11 liquidation filing under bankruptcy. Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.
Pathwork Diagnostics, located in Redwood City, California, specializes in molecular diagnostics for oncology. The company is known for its Pathwork Tissue of Origin Test, which was the first microarray-based gene expression test to receive FDA clearance. This innovative test assists in identifying challenging tumors, including poorly differentiated, undifferentiated, and metastatic cancers. The test leverages genomic information from a tumor to enhance diagnostic precision and can be applied to various specimen types, including frozen tissue and formalin-fixed, paraffin-embedded samples. Through its advanced diagnostic solutions, Pathwork Diagnostics aims to improve clinical outcomes in cancer care.
Broncus Medical develops innovative diagnostic and therapeutic navigation technologies aimed at treating lung diseases. The company offers a range of products, including the Archimedes System, which features bronchoscopic trans-parenchymal needle access for virtual bronchoscopic planning and navigation, and the Lungpoint Virtual Bronchoscopic Navigation system that enables real-time navigation within the lungs for biopsy procedures. Additionally, Broncus is advancing its Exhale product line, which includes the Airway Bypass procedure, a minimally-invasive treatment for homogeneous emphysema, a prevalent form of the disease. The company is currently conducting the pivotal EASE Trial to evaluate this treatment. Founded in 1997 and originally named Broncus Technologies, the company is headquartered in San Jose, California, with additional operations in Shanghai, China, and Mountain View, California. Broncus Medical focuses on addressing the unmet medical needs in interventional pulmonology, improving the diagnosis and treatment of lung cancer and chronic obstructive pulmonary disease (COPD).
Dicerna Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of innovative treatments primarily for liver-related diseases, including rare inherited conditions, chronic liver diseases, and viral infections. Utilizing its proprietary GalXC RNA interference technology, Dicerna focuses on silencing disease-causing genes to address various health issues. Key product candidates include nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B virus infection, and belcesiran for genetic liver disease, among others. The company's extensive research efforts also encompass treatments for cardiovascular diseases and neurodegeneration. Dicerna has established strategic collaborations with prominent pharmaceutical companies to enhance its development capabilities. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna is at the forefront of advancing RNA-based therapeutics.
Labcyte Inc. is a specialized laboratory instrumentation company based in San Jose, California, established in 2000. It focuses on acoustic droplet ejection (ADE) technology, which enables the precise dispensing of nanoliter-scale droplets for various life sciences applications, including drug discovery, genomics research, cancer research, and diagnostic testing. The company's flagship product, Echo, utilizes a focused beam of acoustic energy to transfer small volumes of liquids with high accuracy and minimal waste, thereby reducing consumable costs. Labcyte also offers a range of automation systems, laboratory workstations, and control software to enhance laboratory efficiency. As a subsidiary of Beckman Coulter, Inc., Labcyte has expanded its presence internationally, with offices in countries such as Canada, the United Kingdom, Australia, and several others across Asia. The company was previously known as Picoliter Inc. until it rebranded in 2003.
Hydra Biosciences is a biopharmaceutical company located in Cambridge, Massachusetts, focused on developing innovative drugs for pain, inflammation, cardiovascular diseases, and other conditions. The company utilizes its expertise in novel ion channels, specifically targeting Transient Receptor Potential (TRP) ion channels, to create selective and safer therapeutic options. Hydra employs proprietary high-throughput screening platforms that facilitate the identification and development of drug candidates aimed at addressing significant unmet medical needs. With a strong intellectual property portfolio and a flexible approach to drug discovery, Hydra differentiates itself from traditional biopharmaceutical firms. The company has attracted substantial financing from notable investors, enabling it to advance its drug development programs effectively.
Stanmore Implants Worldwide Ltd. specializes in the design and manufacture of orthopedic implant systems for both juvenile and adult patients, with a focus on orthopedic oncology and complex primary and revision cases affecting the upper limb, lower limb, and pelvis. The company offers a range of adult reconstructive solutions, including modular implant systems for the femur and knee, as well as patient-specific implants tailored for oncology and complex cases. Its juvenile offerings include extendible prostheses designed to accommodate growth. Stanmore Implants is recognized for its innovative approach, which includes a custom implant service and the advancement of robotic bone preparation technology acquired through the purchase of Acrobot. Founded in 1949 and headquartered in Elstree, United Kingdom, Stanmore Implants operates as a subsidiary of Stryker Corporation.
Zogenix, Inc. is a pharmaceutical company focused on developing and commercializing innovative therapies for patients with rare diseases and central nervous system disorders. Headquartered in Emeryville, California, Zogenix is advancing several product candidates, including Fintepla, a low-dose fenfluramine currently undergoing Phase III clinical trials for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. The company is also investigating MT1621, a therapy for inherited mitochondrial DNA depletion disorder. Additionally, Zogenix has established a collaboration with Tevard Biosciences to explore gene therapies for Dravet syndrome and related genetic epilepsies. The company aims to address significant unmet medical needs in the pharmaceutical landscape, particularly for conditions affecting the central nervous system and chronic pain management. Founded in 2006, Zogenix was previously known as SJ2 Therapeutics, Inc. before rebranding in August 2006.
PrimeraDx, Inc. specializes in multiplexed infectious disease assays, focusing on advanced diagnostic technologies. The company offers Scalable Target Amplification Routine technology, enabling the simultaneous quantitative measurement of multiple target nucleic acids. Its product lineup includes ViraQuant, a multiplexed assay for the quantitative measurement of various viruses, as well as FungiQuant Yeast and FungiQuant Mold, which are fungal panels used in mycology testing. Additionally, PrimeraDx provides an instrument designed for the simultaneous detection and quantification of diverse target types, such as mRNA, miRNA, SNPs, and DNA. These products are utilized in various applications, including miRNA analysis, DNA methylation, quantitative genotyping, gene expression, and viral load measurement. Founded in 2004, PrimeraDx is headquartered in Mansfield, Massachusetts.